TF
Serotransferrin
As of the edition of 20 October 2026, TF (serotransferrin, UniProt P02787) has 1 drug tested at it and 2 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P02787
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 69
- Disease areas
- Nutrition and metabolism; Blood and lymph; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Mental health
- Registered trials of its drugs
- 27
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ferric derisomaltose | Marketed | Phase 4 | Ends 2029 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Pharmacosmos | Route B |
| Nippon Shinyaku | Route B |
The other 0 companies at TF
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at TF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.